III

EQS-News: Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda

Retrieved on: 
월요일, 6월 17, 2024
Biosimilar, Neoplasm, PD-L1, IARC, Patient, International, Immune system, Research, EMA, USD, Melanoma, CSO, Risk, Growth, Safety, Recurrence, Pembrolizumab, European Medicines Agency, PD-1, FDA, Food, Lung cancer, Pharmacokinetics, Pharmaceutical industry

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda

Key Points: 
  • Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
    The issuer is solely responsible for the content of this announcement.
  • Press Release // June 13, 2024
    Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
    "Dahlia" investigates the PK equivalence as part of a preventive therapy for patients who have had a malignant melanoma (black skin cancer) completely surgically removed.
  • The start of clinical development of FYB206 underscores Formycon's excellent position among the first three biosimilar development companies for the EU and US market announcing entry into the clinical development phase.
  • Planegg-Martinsried - Formycon AG (FSE: FYB, “Formycon”) announced today that the clinical development program for FYB206, a biosimilar for Keytruda® / pembrolizumab, has started with the inclusion of the first patient.

Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
목요일, 6월 13, 2024
SAN, Therapy, LLP, BRBS, NDA, FDA, Bank statement, Lung cancer, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Aldeyra Therapeutics, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Aldeyra Therapeutics, Inc. against certain of its officers and directors.
  • You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Eagle Pharmaceuticals, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Blue Ridge Bankshares, Inc. against certain of its officers and directors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Direct Digital, Hertz, and Humana and Encourages Investors to Contact the Firm

Retrieved on: 
목요일, 6월 13, 2024
The Hertz Corporation, EVS, P.C, City, EV, ICE, Hertz, Growth, UnitedHealth Group, DRCT, EPS, Defendant, Investment, Machine learning, COVID, Depreciation, Sale, Complaint, News, HTZ

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On this news, Hertz's stock price fell $1.12 per share, or 19.31%, to close at $4.68 per share on April 25, 2024.
  • For more information on the Humana class action go to: https://bespc.com/cases/HUM

Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

Retrieved on: 
수요일, 6월 12, 2024
Zhongshan Hospital, Incidence, Progression-free survival, Cancer, Patient, Public, Marketing, Sorafenib, Death, Liver cancer, Mortality, Safety, Trial of the century, HCC, Human, HKEX, Science, Bevacizumab, Chinese Academy of Sciences, FDA, Survival, Hepatocellular carcinoma, PFS, OS, Diagnosis, Pharmaceutical industry

Junshi Biosciences plans to submit a supplemental new drug application (“NDA”) for this indication to the regulatory authorities in the near future.

Key Points: 
  • Junshi Biosciences plans to submit a supplemental new drug application (“NDA”) for this indication to the regulatory authorities in the near future.
  • According to the GLOBOCAN Report for 2022, there were 866,000 new cases and 759,000 deaths from liver cancer globally that year.
  • The HEPATORCH phase 3 clinical study evaluating toripalimab combined with bevacizumab achieved its primary endpoint, potentially offering a new treatment option with better survival benefits for advanced liver cancer patients.
  • In this study, toripalimab demonstrated its powerful synergy as a cornerstone of immuno-oncology, significantly improving survival rates for patients with advanced HCC.

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

Retrieved on: 
화요일, 6월 11, 2024
DNA, CRADA, Glioblastoma, Development, Patient, Progression-free survival, TCON, Research, Clinical Cancer Research, National Cancer Institute, RNA, Colectomy, Cisplatin, TRACON, DDR, Temozolomide, Glioma, Safety, External beam radiotherapy, Chromosome, Cancer, Oncology, Therapy, Radiation, History, Cleveland Clinic, PDP, NCI, Survival, MD, Lung cancer, Activation, Partnership, Carboplatin, Combination, Pemetrexed, Pharmaceutical industry

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the publication of Phase 2 clinical data of its DNA damage repair inhibitor drug candidate, TRC102, in patients with glioblastoma in Clinical Cancer Research. The article, entitled, “Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT,” highlights the activity of TRC102 given in combination with Temodar chemotherapy in patients with recurrent glioblastoma: https://pubmed.ncbi.nlm.nih.gov/38836759/

Key Points: 
  • The authors concluded the study findings confirm the safety and feasibility of TRC102 given with Temodar for recurrent glioblastoma patients and warrant further evaluation of combination therapy in biomarker-enriched trials enrolling glioblastoma patients with baseline hyperactivated DDR pathways.
  • This trial is sponsored by the National Cancer Institute (NCI) through a Cooperative Research and Development Agreement (CRADA).
  • Determination of the primary endpoint of progression free survival is expected in 2025.
  • TRACON and the NCI have a longstanding history of partnership to develop TRC102, whereby the NCI has funded six Phase 1 or Phase 2 trials through the CRADA.

International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay

Retrieved on: 
화요일, 6월 11, 2024
Prognosis, Health, International Myeloma Foundation, Division, Patient, Mayo Clinic, Research, Amyloid, ASCT, IMF, MRD, Disease, Hope, Biomarker, Multiple myeloma, EMN, Female, Mentorship, Disorder, Empathy, University, Clinical professor, Tumor microenvironment, ASH, Outline of health sciences, Medical device

Durie Outstanding Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.

Key Points: 
  • Durie Outstanding Achievement Awards are presented each year to outstanding and deserving individuals who have made significant contributions in the field of myeloma research.
  • This year’s Robert A. Kyle Lifetime Achievement Awardee is Shaji K. Kumar, MD, Professor of Medicine and Chair of the Myeloma, Amyloid, and Dysproteinemia Group at the Mayo Clinic in Rochester, MN.
  • Dr. Kumar has had a long and sustained impact on the field of myeloma and related disorders.
  • Gay for being this year’s Dr. Durie Outstanding Achievement Awardee: “On behalf of the International Myeloma Foundation (IMF) and the entire myeloma community, I am thrilled to congratulate Dr. Francesca Gay on receiving the Brian G.M.

HERTZ GLOBAL HOLDINGS, INC. (NASDAQ: HTZ) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Hertz Global Holdings, Inc.

Retrieved on: 
월요일, 6월 10, 2024
The Hertz Corporation, EVS, Court, ICE, Action Replay, EPS, HTZ, Defendant, Depreciation, Sale, District court, News, Advertising, Complaint, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Hertz Global Holdings, Inc. (“Hertz” or the “Company”) (NASDAQ: HTZ) between April 27, 2023 and April 24, 2024, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Hertz Global Holdings, Inc. (“Hertz” or the “Company”) (NASDAQ: HTZ) between April 27, 2023 and April 24, 2024, inclusive (the “Class Period”).
  • If you purchased or acquired Hertz securities, and/or would like to discuss your legal rights and options please visit Hertz Global Holdings, Inc.
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Teladoc Health Names Chuck Divita as CEO

Retrieved on: 
월요일, 6월 10, 2024
EVP, GuideWell, First Coast, Teladoc Health, P&C, Therapy, Growth, Certified Public Accountant, Health, Vim, TDOC, Divita Rai, House, Management

Concurrent with his role as CEO, Mr. Divita has also joined Teladoc Health’s Board of Directors as of today.

Key Points: 
  • Concurrent with his role as CEO, Mr. Divita has also joined Teladoc Health’s Board of Directors as of today.
  • Mr. Divita joins Teladoc Health from GuideWell, a leading health solutions organization which includes Florida Blue, the market leading health plan in Florida, where he served as Executive Vice President, Commercial Markets.
  • “In today’s healthcare landscape, Chuck is the perfect example of experience, respect, and competence among executives, and we are pleased to welcome him to Teladoc Health,” said David B.
  • His combination of large healthcare company and public company experience make him a tremendous asset to Teladoc Health.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Direct Digital, Hertz, and Humana and Encourages Investors to Contact the Firm

Retrieved on: 
일요일, 6월 9, 2024
The Hertz Corporation, EVS, P.C, City, EV, ICE, Hertz, Growth, UnitedHealth Group, DRCT, EPS, Defendant, Investment, Machine learning, COVID, Depreciation, Sale, Complaint, News, HTZ

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On this news, Hertz's stock price fell $1.12 per share, or 19.31%, to close at $4.68 per share on April 25, 2024.
  • For more information on the Humana class action go to: https://bespc.com/cases/HUM

Hawthorn Bancshares Announces Results of 2024 Annual Meeting

Retrieved on: 
금요일, 6월 7, 2024
Annual general meeting, LLP

Mr. Burkhead has served as director of Hawthorn Bancshares since 2014 and is currently co-owner of Burkhead & Associates, LLC and owner of Burkhead Wealth Management.

Key Points: 
  • Mr. Burkhead has served as director of Hawthorn Bancshares since 2014 and is currently co-owner of Burkhead & Associates, LLC and owner of Burkhead Wealth Management.
  • Mr. Giles has served as director and Chief Executive Officer of Hawthorn Bancshares since 2023.
  • Mr. States has served as director of Hawthorn Bancshares since 2022 and is currently a member/owner of Little Dixie Construction.
  • Mr. Wetzel has served as director of Hawthorn Bancshares since 2018 and is currently an owner of Meadows Contracting, LLC and Meadows Development Company.